SI
ATYR

Sofinnova Investments’s aTyr Pharma ATYR Stock Holding History

Sofinnova Investments’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-133,295
Closed -$4.95M – 68
2018
Q1 		$4.95M Buy
+133,295
New +$6.25M 0.85% 14

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GHCM
Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return

Sofinnova Investments's ATYR Position: Q2 2018 in Review

Sofinnova Investments sold out of aTyr Pharma (ATYR) in Q2 2018, closing a stake of 133,295 shares — an estimated $4.95M sold.

Sofinnova Investments first reported a position in ATYR in Q1 2018 and held it in 1 quarter. The position peaked at $4.95M in Q1 2018. 33 funds tracked by Wall St. Rank hold ATYR as of Q2 2018.

  • Sofinnova Investments reported no remaining aTyr Pharma position as of Q2 2018 after selling out during the quarter.
  • Sofinnova Investments sold 133,295 aTyr Pharma shares in Q2 2018, an estimated $4.95M.
  • Sofinnova Investments first reported a position in aTyr Pharma in Q1 2018 and held it in 1 quarter.
  • Sofinnova Investments's aTyr Pharma position peaked at $4.95M in Q1 2018.
  • 33 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2018.

Based on Sofinnova Investments's 13F filing for Q2 2018, filed 14 Aug 2018.